Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Goserelin; Letrozole
  • Indications Advanced breast cancer; Carcinoma
  • Focus Adverse reactions

    • Most Recent Events

    • 05 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 14 Feb 2023 Planned End Date changed from 31 Dec 2022 to 30 Apr 2023.
    • 24 Jan 2023 Plasma samples from patients from this study were used to to identify genomic features for predicting and monitoring treatment resistance, published in the Clinical Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top